The heart-wrenching moment of discovering a critical health issue affecting your unborn child is an experience that no parent should have to endure. However, recent advancements in medicine took control of the narrative, before the child was born.
In a historic first, led by researcher Dr. Richard Finkel a now two-year-old girl received prenatal treatment for spinal muscular atrophy (SMA) and is now thriving, showing no signs of the disease. This significant medical advancement is not only a testament to the progress being made in prenatal healthcare but also raises important questions about its implications for the future.
Here’s an exploration of what this achievement signifies, how it was accomplished, and the potential impact it may have on prenatal healthcare moving forward.
What is Spinal Muscular Atrophy (SMA)?
SMA is a genetic disorder that targets motor neurons (specialized nerve cells in the spinal cord that control muscle movements like crawling, walking, and even breathing).
When these “neurons” break down, muscles don’t get the signals they need to be able to move. Over time, the muscles weaken and waste away, leading to severe complications. SMA can affect muscles needed for:
- Breathing
- Swallowing
- Sitting and standing
- Walking
There are five main types of SMA, ranked by severity and age of onset. SMA Type 1 (the most severe) usually shows up in babies before they turn six months old. Without treatment, unfortunately many children with SMA Type 1 don’t survive past their second birthday.
According to Johns Hopkins Medicine, around 1 in 6,000 babies is born with some form of SMA. And when left untreated, Type 1 remains the leading genetic cause of infant death.
What Causes SMA?
The main culprit is a mutated gene (Survival Motor Neuron 1 aka SMN1). This gene’s job is to make an important protein that keeps those motor neurons we talked about healthy and functioning.
When SMN1 is missing or broken, the motor neurons can’t survive, and muscles gradually lose their ability to work.
However, the body does have a backup plan: a second gene called SMN2. This gene can make survival proteins, but in much smaller amounts….not enough to fully protect motor neurons without help.
A New Frontier: Treating SMA Before Birth
Until now, all SMA treatments started after babies were born. But researchers at St. Jude Children’s Research Hospital wondered: What if we could act earlier?
In this case, the baby’s parents had tragically lost a previous child to SMA Type 1. Genetic testing during pregnancy revealed that their next child had inherited the same high-risk mutation.
Rather than wait, doctors asked the FDA for permission to try a new approach: giving the mother a medication called risdiplam (Evrysdi) while she was still pregnant.
How Risdiplam Works
Risdiplam is a medication already FDA-approved for treating SMA after birth. It works by helping the SMN2 gene make more of the survival protein that motor neurons desperately need.
In this unique case:
- The mother took daily doses of risdiplam for the last six weeks of her pregnancy.
- After birth, the newborn continued taking the medication directly.
- Doctors closely monitored both mother and baby for side effects and development.
The results? : Two-and-a-half years later, the child shows no signs of Spinal Muscular Atrophy.
The medication regime created higher SMN protein levels contributing to no motor neuron damage and normal muscle strength and development for the patient.
This is a huge leap forward and not just for SMA, but for the entire field of prenatal intervention.
Why Timing Matters So Much
The third trimester and the first three months after birth are critical windows for motor neuron development. If motor neurons die during this stage, no amount of treatment later can bring them back.
So, with the researchers intervening during pregnancy, this gave the patient a better chance, protecting their muscles and nerves before permanent damage could set in.
With this insight, this could reshape how we think about treating not just SMA, but potentially many other genetic conditions detected during pregnancy.
What This Could Mean for Future Healthcare
While this case involved just one child, it’s an exciting proof of concept. It shows that:
- Safe prenatal treatment is possible.
- We might be able to prevent diseases, not just manage them.
- Earlier interventions could transform outcomes for genetic disorders.
Researchers now hope to launch broader studies to see if prenatal treatment could become a new standard for high-risk pregnancies diagnosed with SMA.
As prenatal genetic testing becomes more advanced, this type of early intervention could become more common.
Imagine a future where many devastating conditions are treated (or even prevented) before birth.
Want to stay informed on the latest in healthcare? Subscribe to the UpNEXHeath blog and get notified when new articles are published!
FAQs –
What is risdiplam?
Risdiplam is an FDA-approved medication for spinal muscular atrophy. It helps increase the production of survival motor neuron (SMN) protein, which is essential for muscle strength.
How is spinal muscular atrophy usually diagnosed?
SMA can be diagnosed through genetic testing, often during pregnancy if parents are known carriers. After birth, it’s typically diagnosed based on symptoms and confirmed with blood tests.
Is prenatal treatment available to everyone?
No, not yet. This was an experimental case with special FDA approval. Broader clinical trials are needed before prenatal risdiplam becomes a routine option.
Will the child have to take medication forever?
Most likely, yes. Experts believe the child will continue taking risdiplam into adulthood to maintain healthy SMN protein levels and motor function.
Can SMA be cured?
Currently, there is no cure for SMA. However, treatments like risdiplam can dramatically slow disease progression and improve quality of life, especially when started early.
Are there risks to treating SMA before birth?
In this case, the treatment was considered safe, with no signs of SMA observed after 2.5 years. However, researchers emphasize that more studies are needed to confirm safety across larger groups.
Leave a Reply